Supplementary Tables – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer

<b>Supplementary Table 1. Baseline Assessment between target US population and ORIENT-11 SPP and PPP arms before and after Adjustment^a</b> <b>Abbreviations: </b>BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; EB, entropy balancing; IPW, inverse probability weighting; N, number of patients in population; n, number of patients in the specified category; PPP, placebo+pemetrexed+platinum; PD-L1, programmed death-ligand 1; SD, standard deviation; SPP, sintilimab+pemetrexed+platinum; SMD, standardized mean difference between SPP and <b>Target US Population or between PPP and Target US Population</b> * Data from Yang et al. 2020 ^aAdjustment refers to IPW (primary analysis) and EB (sensitivity analysis) ^bAge was recorded at first line start date ^cDuration of disease was reported from advanced diagnosis to first line start date